| | | | |
| | | | interest in a party or (b) the power to direct or cause the direction of the management and policies of such party, directly or indirectly, whether through ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing, as the case may be. |
| | |
“Disclosing Party” | | | | has the meaning given in the definition of “Confidential Information”. |
| | |
“Effective Date” | | | | has the meaning given in the preamble of this Agreement. |
| | |
“Establishment Inputs” | | | | means the inputs provided by Catapult set out at Clause 9.3. |
| | |
“Establishment Input Contributions” | | | | means the financial contributions payable in accordance with cause 8.1.5, to be made by COLLABORATOR with respect to the provision of the Establishment Inputs by Catapult, which are detailed in the Establishment Input Statement. |
| | |
“Establishment Input Statement” | | | | means the Establishment Input Contributions Statement by and between Catapult and COLLABORATOR dated 26 November 2019. |
| | |
“Expected Occupation Date” | | | | means 01 March 2020, the contemplated date by which COLLABORATOR will occupy the Manufacturing Space, or such other date as mutually agreed by the parties in writing. |
| | |
“Facility Contribution” | | | | means the contribution to be made by COLLABORATOR with respect to the provision of the Module and other capital aspects, as more particularly described at Clause 8.4.1, and at Schedule 3. |
| | |
“Foreground Intellectual Property” | | | | means the results, technical information, knowledge, inventions, improvements, experience, materials and data developed and arising directly from and as a direct result of the Project, together with any Intellectual Property in such items. |
| | |
“GMP” | | | | means good manufacturing practice, being the standard required to satisfy MHRA GMP requirements. |
| | |
“GMP Requirements” | | | | means good manufacturing practices for medicinal products for human use as applicable in the UK (currently EU GMP Directive 2003/94/EC and as and set out in Volume 4 of Eudralex (the rules governing medicinal products in the European Union), and the MHRA Rules and Guidance for Pharmaceutical Manufacturers and Distributors (The Orange Guide) |
| | |
“Ground Level” | | | | means the Level O Ground Level as shown on the Plans. |
| | |
“Health and Safety Forum” | | | | means the forum in which COLLABORATOR, Other Collaborators, and Catapult will convene to discuss health and safety matters as more particularly described in Clause 9.6 and Schedule 15. |
| | |
“HVAC” | | | | heating, ventilation and air-conditioning. |
| | |
“Improvement” | | | | means, with respect to any Intellectual Property or material: (a) all improvements, modifications and /or adaptions of such Intellectual Property or materials; and (b) all other Intellectual Property in, derived from, relating to, or otherwise within the scope of any claim, right, or interest which would impair or restrict the use of, application, or rights comprised in, such Intellectual Property or material. |
| | |
“Insured Risks” | | | | means the risks covered by the policies of insurance under Clauses 19.1 and 19.2, in each case to the extent that cover is generally available on normal commercial terms in the UK insurance market at the time the insurance is taken out and any other risks against which Catapult reasonably insures from time to time, subject in all cases to any excesses, limitations and exclusions imposed by the insurers. |